Obesity – Current Treatment Insights Report – 2025

Obesity Current Treatment Insights

Thelansis’s “Obesity Current Treatment Insights Report – 2025″ describes the current treatment and management in Obesity. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted.

Obesity Overview

Obesity is a complex, chronic disease characterized by an excessive accumulation of body fat that can impair health. It is a major global health concern with an increasing prevalence driven by a combination of genetic, environmental, social, and psychological factors. From a life science perspective, obesity is not simply a matter of caloric imbalance, but involves intricate hormonal and metabolic dysregulation. Adipose tissue, once considered a passive energy store, is now recognized as a highly active endocrine organ that secretes adipokines, which influence insulin sensitivity, inflammation, and appetite regulation. The disease is a significant risk factor for a wide range of comorbidities, including type 2 diabetes, cardiovascular diseases (hypertension, coronary artery disease, stroke), certain cancers, non-alcoholic fatty liver disease (NAFLD), and musculoskeletal disorders.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician specialty(ies) involved in the diagnosis and treatment of patients:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Patient characteristics/patient segments
• Patient diagnosis criteria
• Patient shares for current therapies
• Line of therapy analysis
• Treatment sequencing
• Patient journey
• Compliance and persistency analysis
• Polypharmacy
• Factors impacting physician choice of treatments
• Drivers and barriers to prescribing key brands/treatments
• Physician-perceived advantages and disadvantages of current therapies
• Evolving treatment landscape
• KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)